Andrew D. Dickinson - Mar 10, 2025 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Role
Chief Financial Officer
Signature
/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson
Stock symbol
GILD
Transactions as of
Mar 10, 2025
Transactions value $
-$1,424,698
Form type
4
Date filed
3/12/2025, 06:41 PM
Previous filing
Feb 19, 2025
Next filing
Mar 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GILD Common Stock Options Exercise $314K +4.92K +2.91% $63.91 174K Mar 10, 2025 Direct F1
transaction GILD Common Stock Options Exercise $832K +13K +7.48% $63.91 187K Mar 10, 2025 Direct F1
transaction GILD Common Stock Sale -$577K -4.92K -2.63% $117.30 182K Mar 10, 2025 Direct F1, F2
transaction GILD Common Stock Sale -$1.54M -13K -7.15% $118.50 169K Mar 10, 2025 Direct F1, F3
transaction GILD Common Stock Options Exercise +7.97K +4.71% 177K Mar 10, 2025 Direct F4
transaction GILD Common Stock Tax liability -$452K -3.86K -2.18% $117.21 173K Mar 10, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GILD Non-qualified Stock Option (Right to Buy) Options Exercise $0 -4.92K -27.42% $0.00 13K Mar 10, 2025 Common Stock 4.92K $63.91 Direct F1, F5
transaction GILD Non-qualified Stock Option (Right to Buy) Options Exercise $0 -13K -100% $0.00 0 Mar 10, 2025 Common Stock 13K $63.91 Direct F1, F5
transaction GILD Restricted Stock Unit Options Exercise -7.97K -22.45% 27.5K Mar 10, 2025 Common Stock 7.97K Direct F4, F6
transaction GILD Non-qualified Stock Option (Right to Buy) Award $0 +49K $0.00 49K Mar 10, 2025 Common Stock 49K $117.21 Direct F5
transaction GILD Restricted Stock Unit Award +11.1K +40.3% 38.6K Mar 10, 2025 Common Stock 11.1K Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
F2 Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F3 Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F5 The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
F6 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.